# SBRA — Sabra Health Care REIT · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** SBRA  
**Sources:** 21  
**Published:** 2026-10-27  
**Canonical:** https://app.k3vl4r.com/research/deep-research-sbra-sabra-health-care-reit-catalysts-narrative-risks-9535

---

# Sabra Health Care REIT (SBRA) — Analysis as of 2026-10-27

## Recent Catalysts (last ~1–3 months)

**July 21, 2026 — Business update with raised guidance.** Sabra issued a business update and increased its full-year 2026 guidance, including normalized FFO of $1.53–$1.55 and normalized AFFO of $1.59–$1.61 per diluted share, representing +7% and +8% growth, respectively, over 2025 [[3]](https://www.nasdaq.com/press-release/sabra-issues-business-update-and-increases-full-year-2026-guidance-2026-07-21). Management attributed much of the upside to portfolio quality improvements, including rent resets and lease amendments that collectively add over $9 million per year in cash NOI run-rate [[3]](https://www.nasdaq.com/press-release/sabra-issues-business-update-and-increases-full-year-2026-guidance-2026-07-21).

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-sbra-sabra-health-care-reit-catalysts-narrative-risks-9535 (free to sign up)._
